Companies › Accro Bioscience (Suzhou)
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Immunology, Other; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AC-101 | – | Phase 2 | Ulcerative Colitis (UC); Ulcerative Colitis | Nov 2027 |
| AC-003 | – | Phase 1 | Acute Graft-versus-Host Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07083193 | AC-101 | Phase 1 | Ulcerative Colitis | Immunology | Apr 2026 |
| NCT07070674 | AC-003 | Phase 1 | Acute Graft-versus-Host Disease | Other | Sep 2026 |
| NCT07755241 | AC-101 | Phase 2 | Ulcerative Colitis (UC) | Immunology | Nov 2027 |
No annotated target.
–
Clarent Biopharma Mirador Therapeutics Shattuck Labs Astria Therapeutics Daewon Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.